Helius Medical Technologies 관리

관리 기준 확인 0/4

주요 정보

Dane Andreeff

최고 경영자

US$602.7k

총 보상

CEO 급여 비율	61.0%
CEO 임기	3.3yrs
CEO 소유권	0.005%
경영진 평균 재임 기간	2.4yrs
이사회 평균 재임 기간	6.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Dane Andreeff 의 보수는 Helius Medical Technologies 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2023	n/a	n/a	-US$13m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$12m
Dec 31 2022	US$603k	US$368k	-US$14m
Sep 30 2022	n/a	n/a	-US$13m
Jun 30 2022	n/a	n/a	-US$17m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$4m	US$192k	-US$18m
Sep 30 2021	n/a	n/a	-US$17m
Jun 30 2021	n/a	n/a	-US$15m
Mar 31 2021	n/a	n/a	-US$13m
Dec 31 2020	US$23k	n/a	-US$14m
Sep 30 2020	n/a	n/a	-US$17m
Jun 30 2020	n/a	n/a	-US$19m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$79k	n/a	-US$10m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	n/a	n/a	-US$8m
Mar 31 2019	n/a	n/a	-US$26m
Dec 31 2018	US$107k	n/a	-US$29m
Sep 30 2018	n/a	n/a	-US$27m
Jun 30 2018	n/a	n/a	-US$36m
Mar 31 2018	n/a	n/a	-US$24m
Dec 31 2017	US$140k	n/a	-US$28m

CEO

Dane Andreeff (57 yo)

3.3yrs

테뉴어

US$602,736

보상

Mr. Dane Carl Andreeff has been the President and Chief Executive Officer of Helius Medical Technologies, Inc. since June 14, 2021 and has been its Director since August 4, 2017. He is the Founder of Andre...

리더십 팀

이름	위치	테뉴어	보상	소유권
Dane Andreeff	President	3.3yrs	US$602.74k	0.0053% € 182.2
Jeffrey Mathiesen	CFO, Treasurer	2.4yrs	US$463.12k	0.042% € 1.5k
Antonella Favit-Van Pelt	Chief Medical Officer	2.3yrs	US$526.55k	0% € 0
Lawrence Picciano	Senior Vice President of Engineering	1.8yrs	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

57yo

평균 연령

이사회 구성원

이름	위치	테뉴어	보상	소유권
Dane Andreeff	President	6.3yrs	US$602.74k	0.0053% € 182.2
Jeffrey Mathiesen	CFO, Treasurer	1.5yrs	US$463.12k	0.042% € 1.5k
Edward Straw	Independent Director	9yrs	US$86.04k	0.025% € 856.2
Paul Buckman	Independent Director	2.2yrs	US$89.04k	0.024% € 819.8
Robert Walter	Independent Chairman of the Board	7.9yrs	US$104.04k	0.037% € 1.3k
Ali Rezai	Member of Scientific Advisory Board	6.3yrs	데이터 없음	데이터 없음
Raj Narayan	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Carl Hauser	Member of Scientific Advisory Board	9yrs	데이터 없음	데이터 없음
Sherry Perkins	Independent Director	2.7yrs	US$75.54k	0.014% € 491.9
Deborah Backus	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

6.3yrs

평균 재임 기간

64.5yo

Helius Medical Technologies 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Helius Medical Technologies, Inc., Annual General Meeting, Jun 27, 2024

Helius Medical Technologies, Inc., Annual General Meeting, May 23, 2022

Helius Medical Technologies, Inc. Appoints Sherrie Perkins to the Board of Directors

Helius Medical Technologies, Inc. Announces CEO Changes

Recent updates

Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study

Helius Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Helius Medical Technologies, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Helius Medical Technologies, Inc. Completes Site Participation Enrollment for Its U.S. Registrational Program in Stroke

Helius Medical Technologies, Inc., Annual General Meeting, Jun 27, 2024

Helius Medical Technologies, Inc. Announces Pons Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts

Helius Medical Technologies, Inc. to Report Q1, 2024 Results on May 13, 2024

Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center

Helius Medical Technologies, Inc. has filed a Follow-on Equity Offering.

Helius Medical Technologies Receives Written Notice from the Nasdaq Stock Market

Helius Medical Technologies, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke

Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients

Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital

Helius Medical Technologies, Inc. Announces Impairment Charges for the Three Months Ended September 30 2023

Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy(TM) Helps Patients with Traumatic Brain Injury Return to Work

Helius Medical Technologies, Inc. Provides Financial Guidance for the Third Quarter of 2023

Helius Medical Technologies, Inc. Provides Financial Guidance for the Third Quarter of 2023

Helius Medical Technologies, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Helius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria

Helius Medical Technologies, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2023

Helius Medical Technologies, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Helius Medical Technologies, Inc. to Report Q1, 2023 Results on May 11, 2023

Helius Medical Technologies to Showcase PoNS Therapy™ at American Physical Therapy Association’s 2023 Combined Sections Meeting

Helius Medical Technologies, Inc. Provides Revenue Guidance for the fourth quarter and Full Year Ended December 31, 2022

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Forth Quarter and Full Year Ended December 31, 2022

Helius Medical Technologies, Inc. Reports Impairment Results for the Quarter Ended September 30, 2022

Helius Medical Technologies, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Helius Medical Technologies Receives Non-Compliance Notice from Nasdaq

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Third Quarter for 2022

Helius Medical Technologies, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Helius Medical Technologies, Inc. Announces Online Training for PoNS Therapy

Helius Medical Technologies, Inc. Announces Launch of Patient Therapy Access Program for PoNS®

Helius Medical Technologies, Inc. Provides Earnings Guidance for the Second Quarter of 2022

Helius Medical Technologies, Inc. to Report Q1, 2022 Results on May 12, 2022

Helius Medical Technologies, Inc. Introduces Device in U.S. to Help Multiple Sclerosis Patients Improve Walking Ability

Helius Medical Technologies, Inc., Annual General Meeting, May 23, 2022

Helius Medical Technologies, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2021

Helius Medical Technologies, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Helius Medical Technologies Announces Voluntary De-Listing from Toronto Stock Exchange

Second quarter 2021 earnings released: US$2.58 loss per share (vs US$2.90 loss in 2Q 2020)

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Second Quarter of 2021

Helius Medical Technologies, Inc. Not Providing Earnings Guidance for 2021, Due to COVID-19

Helius Medical Technologies, Inc. Appoints Sherrie Perkins to the Board of Directors

Helius Medical Technologies, Inc. Not to Provide Formal Financial Outlook for the Full Year 2021 At This Time

Helius Medical Technologies, Inc. to Report Q4, 2020 Results on Mar 10, 2021

Helius Medical Technologies, Inc. has completed a Composite Units Offering in the amount of $9.599981 million.

Helius Medical Technologies, Inc. Regains Compliance with Nasdaq Listing Standards

Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the Ponstm Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis

New 90-day low: €0.30

Revenue beats expectations

Third quarter 2020 earnings released: US$0.077 loss per share

Helius Medical Technologies, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Helius Medical Technologies, Inc. announced that it has received $3.44419 million in funding from Maple Leaf Investments and other investors

Helius Medical Technologies, Inc. Announces Partnership with Breakthrough Health for Multiple Sclerosis Insights

Helius Medical Technologies, Inc. Announces CEO Changes

Helius Medical Technologies, Inc. Unable to Estimate the Duration and Impact of the COVID-19 Pandemic on its Financial and Operating Results for the Full Year 2020

Earnings released

Helius Medical Technologies, Inc. to Report Q2, 2020 Results on Aug 12, 2020

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령